As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner. Here, we introduce our IVD antibody development services targeting the FGF23 marker.

Fibroblast Growth Factor 23 (FGF23)

Fibroblast growth factor 23 (FGF23) encodes a protein which belongs to the fibroblast growth factor family. This protein possesses broad mitogenic and cell survival activities. In addition, they are involved in a variety of biological processes. FGF23 regulates phosphate homeostasis and transport in the kidney. FGF23 inhibits renal phosphate reabsorption and renal phosphate transporter expression. Infusion or overexpression of FGF23 in animals or in humans results in the inhibition of 1-alpha hydroxylase. Physiological triggers of FGF23 synthesis are high blood phosphate and calcitriol concentrations.

FGF23 is a leading cause of various diseases.

FGF23 Marker of Fibrosis

The liver expresses several fibroblast growth factors including FGF1, FGF2, FGF19, FGF21, FGF23. Substantial evidence implicates FGF signaling in normal liver function and its dysregulation in chronic liver disease. Infusion or overexpression of FGF23 in animals or in humans results in the inhibition of 1-alpha hydroxylase (CYP27B1) activity in the kidney and the reduction of serum calcitriol concentration. Physiological triggers of FGF23 synthesis are high blood phosphate and calcitriol concentrations. FGF23 concentration also increases early with the decline of renal function. FGF23 affinity for FGF receptors (FGFR) is low. At physiological concentration, FGF23 action requires the presence at the cell surface of a FGFR (type 1, 3 or 4) and the protein named αKlotho whose expression is restricted to few tissues. Serum sodium concentration is also a predictive factor in patients with liver cirrhosis and its combination with the MELD score has ameliorated the prediction of mortality. FGF23 concentration can be measured quite easily by enzyme-link immunosorbent assay (ELISA).

Expression of FGF23 in liver tissue from case 2 obtained at the time of Kasai portoenterostomy. Fig.2 Expression of FGF23 in liver tissue from case 2 obtained at the time of Kasai portoenterostomy. (Halley Wasserman., 2016)

Antibody Development Services for FGF23 Marker

Antibodies are core elements for antibody-based immunoassays for detecting and quantifying antigens of interest in all kinds of samples such as the serum, urine, tissue preparations, and so on. IVD antibodies are extensively used for disease screening, prognosis, and therapeutic monitoring. With our versatile IVD platform, Creative Biolabs is proud to develop novel anti-FGF23 antibodies from scratch to commercial IVD kit.

For more detailed information, please feel free to contact us or directly send us an inquiry. Once receiving your inquiry, our scientists will feedback on your project as soon as possible, come up with a complete quotation including details of products, shipping, and the final report.

Reference

  1. Halley Wasserman., (2016) “Two Case Reports of FGF23-Induced Hypophosphatemia in Childhood Biliary Atresia.” Pediatrics, 138: e1-e6.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.